English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The inhibitory effect of EMD 26644 on platelet function has been studied with the following methods: spontaneous aggregation (PAT III), ADP-, collagen-and epinephrire-induced aggregation, primary shape change of thrombocytes at 37°C incubation temperature and platelet spreading.  Duke’s bleeding time, platelet count and some coagulation parameters like partial thromboplastin time, Quick’s test, fibrinogen, thrombin time and factor VII-assay as well as platelet spreading were unchanged throughout the test period.  An aspirin like inhibitory effect on platelet aggregation and primary shape change was observed 48 – 72 hrs. after the ingestion of a single dose of 250 mg EMD, which lasted for 2–3 weeks. A prolonged antiaggregating effect was achieved by the continuous oral administration of 25 – 50 mg EMD for a period of 2 – 3 months. No potentiation of the antiaggregating effect was seen, if ASA was given in addition to EMD 26644.  In comparison with aspirin the new compound seems to have some advantages: the same antiplatelet properties are achieved with a much lower dose and no side effects have been reported so far. Clinical studies will have to confirm whether EMD 26644 is an effective antithrombotic agent.

In Vivo Studies with a New Antiaggregating Drug EMD 26644, A Mercapto-Oxazolyl-Carbon-Acid Derivative